Invivyd (IVVD) Research & Development (2021 - 2025)
Invivyd (IVVD) posted Research & Development of $10.0 million for Q4 2025, up 24.88% on a QoQ basis from $8.0 million in Q3 2025, and down 43.9% year-over-year from $17.9 million in Q4 2024.
Invivyd (IVVD) Research & Development (2021 - 2025) Analysis & Trends
Invivyd's Research & Development history runs 5 years deep, the most recent figure standing at $10.0 million for Q4 2025.
- Quarterly Research & Development fell 43.9% year-over-year to $10.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $38.3 million (down 72.09% YoY) and the FY2025 annual result came in at $38.3 million, down 72.09% from the prior year.
- Research & Development was $10.0 million for Q4 2025 at Invivyd, up from $8.0 million in the prior quarter.
- Across five years, Research & Development topped out at $92.0 million in Q1 2022 and bottomed at $8.0 million in Q3 2025.
- A 5-year average of $34.8 million and a median of $30.7 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development surged 212.59% — and 2025, when it tumbled 86.09%.
- Invivyd's Research & Development stood at $68.4 million in 2021, then tumbled by 70.89% to $19.9 million in 2022, then jumped by 212.59% to $62.3 million in 2023, then tumbled by 71.24% to $17.9 million in 2024, then plunged by 43.9% to $10.0 million in 2025.
- Business Quant data shows IVVD's Research & Development at $10.0 million in Q4 2025, $8.0 million in Q3 2025, and $9.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | 1.46 Mn |
| 4 | BeOne Medicines | 472.06 Bn | 467.27 Bn | 1.35 Bn | 541.22 Mn |
| 5 | Vertex Pharmaceuticals | 122.10 Bn | 114.85 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.25 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.50 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Invivyd | 104.74 Mn | -121.95 Mn | 16.07 Mn | 10.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 10.05 Mn |
| Sep 30, 2025 | 8.05 Mn |
| Jun 30, 2025 | 9.57 Mn |
| Mar 31, 2025 | 10.64 Mn |
| Dec 31, 2024 | 17.91 Mn |
| Sep 30, 2024 | 57.85 Mn |
| Jun 30, 2024 | 30.33 Mn |
| Mar 31, 2024 | 31.16 Mn |
| Dec 31, 2023 | 62.27 Mn |
| Sep 30, 2023 | 25.57 Mn |
| Jun 30, 2023 | 43.62 Mn |
| Mar 31, 2023 | 27.20 Mn |
| Dec 31, 2022 | 19.92 Mn |
| Sep 30, 2022 | 30.13 Mn |
| Jun 30, 2022 | 37.13 Mn |
| Mar 31, 2022 | 92.04 Mn |
| Dec 31, 2021 | 68.43 Mn |
| Sep 30, 2021 | 45.37 Mn |
| Jun 30, 2021 | 35.07 Mn |
| Mar 31, 2021 | 34.03 Mn |